Skip Navigation
Menu
Editorials |6 September 2016

Pioglitazone: An Addition to Our Toolbox for Patients With Diabetes and Nonalcoholic Steatohepatitis?

Eduardo Vilar-Gomez, MD, PhD; Leon A. Adams, MBBS, PhD

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
This article was published at www.annals.org on 21 June 2016.
  • From University of Seville, Seville, Spain, and University of Western Australia, Nedlands, Australia.

    Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M16-1303.

    Requests for Single Reprints: Eduardo Vilar-Gomez, MD, PhD, Unit for the Clinical Management of Digestive Diseases, Virgen Macarena-Virgen del Rocio University Hospitals, Institute of Biomedicine, Ciberehd, University of Seville, Manuel Siurot Avenue, s/n, Seville, Spain; e-mail, eduardovilar2000@yahoo.com.

    Current Author Addresses: Dr. Vilar-Gomez: Unit for the Clinical Management of Digestive Diseases, Virgen Macarena-Virgen del Rocio University Hospitals, Institute of Biomedicine, Ciberehd, University of Seville, Manuel Siurot Avenue, s/n, Seville, Spain.

    Dr. Adams: School of Medicine and Pharmacology, University of Western Australia, M50, Nedlands, Western Australia 6009, Australia.

×
FULL TEXT
Nonalcoholic fatty liver disease (NAFLD) is a growing global public health problem and is now recognized as the most common cause of chronic liver disease in the United States and other industrialized countries (1). The prevalence of NAFLD has increased in parallel with the dramatic increase in obesity and type 2 diabetes mellitus (T2DM), and it is now estimated to occur in more than 30% of the adult U.S. population (1). Although most patients with NAFLD have simple steatosis and a relatively benign clinical course, a smaller proportion develop nonalcoholic steatohepatitis (NASH), which may progress to cirrhosis and liver cancer and increases the risk for cardiovascular and chronic kidney disease (1). Moreover, the presence of NASH and significant fibrosis increases the likelihood of all-cause death, liver transplantation, and liver-related complications (2, 3). The presence of T2DM in patients with NASH is strongly associated with fibrosis severity and mortality risk (4). Therefore, patients with T2DM particularly need therapies that modify the natural history of NAFLD and NASH.
FULL TEXT
PDF
Not Available
Citations
Citation

Vilar-Gomez E, Adams LA. Pioglitazone: An Addition to Our Toolbox for Patients With Diabetes and Nonalcoholic Steatohepatitis?. Ann Intern Med. ;165:373–374. doi: 10.7326/M16-1303

Download citation file:

© 2019

×
Permissions

Published: Ann Intern Med. 2016;165(5):373-374.

DOI: 10.7326/M16-1303

Published at www.annals.org on 21 June 2016

©
2016 American College of Physicians
1 Citations

Related Articles
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial
Annals of Internal Medicine; 165 (5): 305-315
Pioglitazone for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes
Annals of Internal Medicine; 165 (5): I-15
Annals for Educators - 6 September 2016
Annals of Internal Medicine; 165 (5): ED5
Vitamin E, but not pioglitazone, improved nonalcoholic steatohepatitis in nondiabetic patients
Annals of Internal Medicine; 153 (6): JC3-12
View MoreView Less

Journal Club
Vitamin E, but not pioglitazone, improved nonalcoholic steatohepatitis in nondiabetic patients
Annals of Internal Medicine; 153 (6): JC3-12
Pioglitazone reduced liver injury and improved fasting glucose in nonalcoholic steatohepatitis without diabetes
Annals of Internal Medicine; 150 (2): JC1-9
Protocol-based nurse management of type 2 diabetes did not differ from usual GP care for HbA1c levels
Annals of Internal Medicine; 155 (6): JC3-7
Review: Rosiglitazone increases risk for cardiovascular outcomes and mortality compared with pioglitazone in type 2 diabetes
Annals of Internal Medicine; 155 (4): JC2-12
View MoreView Less

Related Point of Care
Nonalcoholic Fatty Liver Disease
Annals of Internal Medicine; 169 (9): ITC65-ITC80
View MoreView Less

Related Topics
Cardiology
Coronary Risk Factors
Diabetes
Endocrine and Metabolism
Gastroenterology/Hepatology

Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism, Gastroenterology/Hepatology.

PubMed Articles
Comparisons of Three Main Treatments on Renoprotective Effects in Diabetes Mellitus.
Iran J Kidney Dis 2019;13(1):36-47.
Lactate accelerates calcification in VSMCs through suppression of BNIP3-mediated mitophagy.
Cell Signal 2019.
View More

Results provided by: PubMed

CONTINUE WITH LIMITED ACCESS
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×